Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device Deals

Financings In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

Tria Beauty postpones IPO. Agendia raises $65 million for cancer tests. Kona Medical gets $30 million for hypertension device development. More financings.

You may also be interested in...



News In Brief

McKesson buys PSS World Medical. St. Jude Medical draws FDA form 483. Cibiem raises $10 million for heart failure, hypertension treatment. More news briefs.

People In Brief

Heartware and Agendia appoint new chief financial officers. More people briefs.

New Products In Brief

A drug-eluting stent and prostate cancer assay are among newly approved devices.

Table

View full table

Related Content

Medtech Insight
Medtech Insight
Medtech Insight
Medtech Insight
Medtech Insight

Topics

Related Companies

Tags:
Medical Device Deals
Latest Headlines

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion

Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations

See All
UsernamePublicRestriction

Register

MT031271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By